Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...

Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how Breakthrough Therapy Designation and ...

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; ...

Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.

Dirk Schadendorf, MD, discusses where triplet therapy fits for BRAF V600-mutant melanoma following the results of the STARBOARD trial.

The IMpactMF trial was discontinued after an independent committee determined imetelstat was unlikely to improve overall ...

Merieme Klobocista, MD, of Hackensack Meridian Health explains how molecular testing is personalizing treatment for ovarian ...

The first-in-class oral RIPTAC molecule JNJ-6143 reached a 75% overall response rate and significant declines in PSA in ...

Obesity and lung cancer research shows mixed results; experts urge moving beyond BMI to waist metrics and CT-based body ...